Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
04/2012
04/19/2012WO2012003452A3 Perlecan domain v protects, repairs and restores ischemic brain stroke injury and motor function
04/19/2012WO2011163669A3 Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
04/19/2012WO2011159839A3 Thioacetate compounds, compositions and methods of use
04/19/2012WO2011153192A3 Cytochrome p450 inhibitors and uses thereof
04/19/2012WO2011152662A9 Ptd-uqcrb fusion polypeptide, and pharmaceutical composition for preventing and treating ischemic diseases, containing same
04/19/2012WO2011149981A3 Oral formulations for counteracting effects of aging
04/19/2012WO2011149206A3 Pharmaceutical composition containing crystalline nebivolol hydrochloride and method for preparing the same
04/19/2012WO2011127393A3 Variants of ancestral uricases and uses thereof
04/19/2012WO2011119939A3 Manipulation of calcium channels to regulate after-depolarization events in cardiac myocytes
04/19/2012WO2011104588A3 Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation
04/19/2012US20120095390 Generation of Therapeutic Microfoam
04/19/2012US20120095386 Composition and device structure for iontophoresis
04/19/2012US20120095108 Composition containing microbial zeaxanthin and preparation thereof
04/19/2012US20120095107 Methods for treatment of cardiovascular disorders and diseases
04/19/2012US20120095104 Use of vasoconstrictors
04/19/2012US20120095102 Salts of 3-Pentylphenylacetic Acid and Pharmaceutical Uses Thereof
04/19/2012US20120095099 Trans carotenoids, their synthesis, formulation and uses
04/19/2012US20120095095 Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
04/19/2012US20120095091 Antiepileptic, hypocholesterolemic and neuroprotective compound
04/19/2012US20120095089 Schweinfurthins and uses thereof
04/19/2012US20120095081 Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
04/19/2012US20120095073 Ion channel modulating activity ii
04/19/2012US20120095072 Crystalline Sodium Atorvastatin
04/19/2012US20120095071 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
04/19/2012US20120095069 Pharmaceutical oral telmisartan solution
04/19/2012US20120095067 Pharmaceutical composition containing carboxylosartan and a production method therefor
04/19/2012US20120095065 Macrocyclic compounds and methods of treatment
04/19/2012US20120095063 Methods and compositions for treatment of ischemic conditions and conditions related to mitochondrial function
04/19/2012US20120095056 2,5-disubstituted tetrazole derivatives and their use as nicotinic acetylcholine receptor modulators
04/19/2012US20120095052 Par-1 antagonism in fed or antacid-dosed patients
04/19/2012US20120095049 Nociceptin analogs
04/19/2012US20120095046 Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders
04/19/2012US20120095040 Cyclopenta[c]pyrrole-2-carboxylate derivatives, preparation thereof and therapeutic use thereof
04/19/2012US20120095033 Selective Glycosidase Inhibitors and Uses Thereof
04/19/2012US20120095028 3-oxa-7-azabicyclo[3.3.1]nonanes
04/19/2012US20120095025 SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
04/19/2012US20120095024 Toluidine sulfonamides and their use
04/19/2012US20120095020 Cathepsin S Inhibitor Compounds
04/19/2012US20120095013 Use of kmup-3 for myocardial infarction
04/19/2012US20120095012 Toluidine sulfonamides and their use
04/19/2012US20120095010 Tricyclic delta-opioid modulators
04/19/2012US20120095006 Treatment of pulmonary hypertension
04/19/2012US20120095005 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors
04/19/2012US20120095004 Sphingosine Kinase Inhibitors
04/19/2012US20120095003 Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof
04/19/2012US20120095000 Compounds for activating tgf-beta signaling
04/19/2012US20120094996 Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives
04/19/2012US20120094993 N-pyridin-3-yl or n-pyrazin-2-yl carboxamides
04/19/2012US20120094992 Poly (adp-ribose) polymerase (parp) inhibitors
04/19/2012US20120094990 Phenylacetic acid compound
04/19/2012US20120094989 5-ht receptor modulating compounds
04/19/2012US20120094987 SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-alpha
04/19/2012US20120094983 Acyclic ikur inhibitors
04/19/2012US20120094980 Pyridyl inhibitors of hedgehog signalling
04/19/2012US20120094979 Thiazole or thiadizaloe derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
04/19/2012US20120094973 Catechol-based derivatives for treating or preventing diabetics
04/19/2012US20120094970 NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE
04/19/2012US20120094968 Sulfonic amide and sulfoximine-substttuted diaryl-dihydropyrimidinones and usage thereof
04/19/2012US20120094966 Organic compounds
04/19/2012US20120094964 Sulfamoyl benzoic acid derivatives as trpm8 antagonists
04/19/2012US20120094957 Inhibitors of fatty acid amide hydrolase
04/19/2012US20120094944 Novel imidazopyridine compound
04/19/2012US20120094943 Alpha 7 nicotinic receptor selective ligands
04/19/2012US20120094941 Mangiferin-Berberine Salt, Manufacturing Method and Use Thereof
04/19/2012US20120094934 Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
04/19/2012US20120094904 Fad4, fad5, fad5-2, and fad6, novel fatty acid desaturase family members and uses thereof
04/19/2012US20120094895 Method for enhancing phagocytosis of phosphatidylserine-exposing cells
04/19/2012US20120094894 Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
04/19/2012US20120094293 PGC-1ß, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
04/19/2012US20120093948 Nitric Oxide Treatments
04/19/2012US20120093941 Neutrophil-depleted platelet rich plasma formulations for cardiac treatments
04/19/2012US20120093933 Denatured lactoglobulin and polyphenol coassemblies
04/19/2012US20120093931 Inhibition of Neovascularization by Cerium Oxide Nanoparticles
04/19/2012US20120093925 Oral medicinal composition and oral medicinal capsule having the composition encapsulated therein
04/19/2012US20120093922 Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
04/19/2012US20120093912 Biomimetic Nanofiber Web And Method And Device To Manufacture The Same
04/19/2012US20120093887 Amorphous varenicline tartrate co-precipitates
04/19/2012US20120093885 Therapeutic vesicles
04/19/2012US20120093879 Cardiac stem cells and uses of same in cardiac repair
04/19/2012US20120093836 Pharmaceutical compositions for treating metastasis
04/19/2012US20120093833 Human Oncostatin M Antibodies and Methods of Use
04/19/2012US20120093829 New methods for treatment of inflammatory diseases
04/19/2012US20120093814 Fusion Proteins Comprising Canine FC Portions
04/19/2012US20120093797 Combined use of creatine phosphate and creatine phosphokinase for treatment of arteriosclerosis
04/19/2012US20120093796 Novel use of ec-sod and method for preparing thereof
04/19/2012US20120093789 Methods of Modulating Smooth Muscle Cell Proliferation and Differentiation
04/19/2012US20120093786 Treatment of limb ischemia
04/19/2012US20120093776 Methods for treating diseases using a bone morphogenetic protein
04/19/2012US20120093764 Treatment of diabetes using g-csf and hyperbaric oxygen
04/19/2012US20120093725 Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies
04/19/2012US20120093722 Synthetic diblock copolypeptide hydrogels for use in the central nervous system
04/19/2012DE102010048374A1 Pyrrolidinone als MetAP-2 Inhibitoren Pyrrolidinone as MetAP-2 inhibitors
04/19/2012DE102010014412A1 Use of dinuclear iron complexes having sulfur-containing ligands as carbon monoxide-releasing pharmacological agents e.g. for treating hypertension, cancer, tissue damage by irradiation, post-ischemic injury, atherosclerosis or sepsis
04/19/2012CA2814713A1 Cardiac induced pluripotent stem cells and methods of use in repair and regeneration of myocardium
04/19/2012CA2814628A1 Acylbenzene derivative
04/19/2012CA2814518A1 Compositions and methods of treating pulmonary hypertension
04/19/2012CA2814495A1 Clevidipine emulsion formulations containing antimicrobial agents
04/19/2012CA2813520A1 N-pyridin-3-yl or n-pyrazin-2-yl carboxamides
04/18/2012EP2441833A1 Aptamer for chymase, and use thereof
04/18/2012EP2441458A1 A vascular protecting agent having salt-absorption inhibitory activity
1 ... 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 ... 1595